Rapid ischemic tolerance: Ubiquitin-mediated structural reorganization
快速缺血耐受:泛素介导的结构重组
基本信息
- 批准号:7149477
- 负责人:
- 金额:$ 17.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-01 至 2008-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Tolerance, the cellular response to mild stress, which protects against a toxic stress, is a conserved feature of many organisms. Most research has focused on long-term tolerance, which occurs 24-72 hours following preconditioning and is mediated by changes in gene expression. In contrast we have focused on short-term ischemic tolerance, which is mediated by rapid biochemical events and occurs 1 hour following the preconditioning. The identification of the mechanisms of short-term tolerance may identify novel rapid acting therapeutic targets to treat acute ischemic episodes (stroke). Our studies have suggested the ubiquitin-proteasome system, which regulates protein degradation, as being responsible for rapid ischemic tolerance. Using a proteomics screen we identified 2 candidate proteins, fascin and myristilated alanine-rich C kinase substrate (MARCKS), which are selectively ubiquitinated and degraded following preconditioning ischemia. The degradation of these candidate proteins results in the reorganization of the actin cytoskeleton, and may reduce NMDA receptor function, which is implicated in excitotoxic cell injury following ischemia. Our central hypothesis is the degradation of fascin and MARCKS following preconditioning ischemia, results in brief cytoskeleton re-arrangement and disruption of NMDA receptor function thereby protecting the brain from harmful ischemia. Our hypothesis will be tested using an in vitro model of ischemia. In Aim 1, Investigate the effect of preconditioning ischemia on cytoskeletal protein degradation by the ubiquitin-proteasome system, we will investigate the role of the ubiquitin-proteasome system on the rapid degradation of our two candidate proteins, fascin and MARCKS, following preconditioning ischemia. In the Aim 2, Investigate changes in postsynaptic structural reorganization in ischemic tolerance, we will study the effect of preconditioning ischemia on the reorganization of the postsynaptic membrane. Experiments will address the effect of preconditioning ischemia on the structure of dendrites. We will determine the relevance of actin reorganization on ischemic tolerance by using actin stabilizing/ destabilizing compounds. Using co- immunoprecipitation we will investigate actin-NMDA receptor interactions following preconditioning. Understanding how preconditioning remodels synaptic structure and function may help identify harmful vs. protective mechanisms induced by brief ischemia in the brain, and give a clearer understanding of brain cell death. We believe that the rapid and selective degradation of specific brain proteins induces a protective state and may reveal suitable targets for pharmacological therapeutics. Indeed, the long-term aim of these studies is to discover endogenous protective mechanisms that can be translated into effective rapid acting neuroprotective agents for stroke.
描述(由申请人提供):耐受性是对轻度应激的细胞反应,可保护免受毒性应激,是许多生物体的保守特征。大多数研究都集中在长期耐受性,这发生在预处理后24-72小时,并通过基因表达的变化介导。相反,我们关注的是短期缺血耐受,它是由快速的生化事件介导的,发生在预处理后1小时。短期耐受机制的确定可能会发现新的快速作用的治疗靶点,以治疗急性缺血发作(中风)。我们的研究表明,泛素-蛋白酶体系统,调节蛋白质降解,是负责快速缺血耐受。使用蛋白质组学筛选,我们确定了2个候选蛋白,肌成束蛋白和豆蔻酰化的富含丙氨酸的C激酶底物(MARCKS),这是选择性泛素化和降解后预处理缺血。这些候选蛋白的降解导致肌动蛋白细胞骨架的重组,并可能降低NMDA受体功能,这与缺血后的兴奋性毒性细胞损伤有关。我们的中心假设是预处理缺血后肌成束蛋白和MARCKS的降解,导致短暂的细胞骨架重排和NMDA受体功能的破坏,从而保护脑免受有害的缺血。我们的假设将使用缺血的体外模型进行测试。目的一:研究缺血预处理对泛素-蛋白酶体系统降解细胞骨架蛋白的影响,我们将研究泛素-蛋白酶体系统在缺血预处理后fascin和MARCKS两种候选蛋白快速降解中的作用。目的二:探讨缺血耐受中突触后结构重组的变化,我们将研究缺血预处理对突触后膜重组的影响。实验将解决预处理缺血对树突结构的影响。我们将通过使用肌动蛋白稳定/去稳定化合物来确定肌动蛋白重组对缺血耐受的相关性。使用免疫共沉淀法,我们将研究预处理后肌动蛋白-NMDA受体的相互作用。了解预处理如何重塑突触结构和功能可能有助于识别大脑短暂缺血诱导的有害机制与保护机制,并更清楚地了解脑细胞死亡。我们认为,特定脑蛋白的快速和选择性降解诱导保护状态,并可能揭示合适的药物治疗靶点。事实上,这些研究的长期目标是发现内源性保护机制,可以转化为有效的快速作用的神经保护剂中风。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT MELLER其他文献
ROBERT MELLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT MELLER', 18)}}的其他基金
Blood transcriptomics as CT adjuvant to exclude hemorrhage in acute stroke
血液转录组学作为 CT 佐剂排除急性中风出血
- 批准号:
10611988 - 财政年份:2020
- 资助金额:
$ 17.44万 - 项目类别:
Blood transcriptomics as CT adjuvant to exclude hemorrhage in acute stroke
血液转录组学作为 CT 佐剂排除急性中风出血
- 批准号:
10396630 - 财政年份:2020
- 资助金额:
$ 17.44万 - 项目类别:
Blood transcriptomics as CT adjuvant to exclude hemorrhage in acute stroke
血液转录组学作为 CT 佐剂排除急性中风出血
- 批准号:
10210310 - 财政年份:2020
- 资助金额:
$ 17.44万 - 项目类别:
Rapid ischemic tolerance: Synaptic re-organization and reduced excitotoxicity
快速缺血耐受:突触重组和兴奋性毒性降低
- 批准号:
8142097 - 财政年份:2008
- 资助金额:
$ 17.44万 - 项目类别:
Rapid ischemic tolerance: Synaptic re-organization and reduced excitotoxicity
快速缺血耐受:突触重组和兴奋性毒性降低
- 批准号:
8332845 - 财政年份:2008
- 资助金额:
$ 17.44万 - 项目类别:
Rapid ischemic tolerance: Synaptic re-organization and reduced excitotoxicity
快速缺血耐受:突触重组和兴奋性毒性降低
- 批准号:
7915525 - 财政年份:2008
- 资助金额:
$ 17.44万 - 项目类别:
Rapid ischemic tolerance: Synaptic re-organization and reduced excitotoxicity
快速缺血耐受:突触重组和兴奋性毒性降低
- 批准号:
7694369 - 财政年份:2008
- 资助金额:
$ 17.44万 - 项目类别:
Rapid ischemic tolerance: Synaptic re-organization and reduced excitotoxicity
快速缺血耐受:突触重组和兴奋性毒性降低
- 批准号:
7583695 - 财政年份:2008
- 资助金额:
$ 17.44万 - 项目类别:
Rapid ischemic tolerance: Ubiquitin-mediated structural reorganization
快速缺血耐受:泛素介导的结构重组
- 批准号:
7282685 - 财政年份:2006
- 资助金额:
$ 17.44万 - 项目类别:
Protein ubiquitination based neuroprotection for stroke
基于蛋白质泛素化的中风神经保护
- 批准号:
6862336 - 财政年份:2005
- 资助金额:
$ 17.44万 - 项目类别:
相似海外基金
Regulation of GluN2B-NMDA Receptors by Interactions with the Actin Cytoskeleton
通过与肌动蛋白细胞骨架相互作用调节 GluN2B-NMDA 受体
- 批准号:
10606121 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Develop and Assess mRNA Lipid Nanoparticle Vaccines Against Cryptococcosis
开发并评估针对隐球菌病的 mRNA 脂质纳米颗粒疫苗
- 批准号:
10616313 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Molecular Tool Development to Identify, Isolate, and Interrogate the Rod Microglia Phenotype in Neurological Disease and Injury
开发分子工具来识别、分离和询问神经系统疾病和损伤中的杆状小胶质细胞表型
- 批准号:
10599762 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Investigating the mechanisms of stereocilia length regulation and innovative strategies for restoring hearing
研究静纤毛长度调节机制和恢复听力的创新策略
- 批准号:
10678569 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Brain derived extracellular vesicles-mediated neurotoxicity of deltamethrin
溴氰菊酯脑源性细胞外囊泡介导的神经毒性
- 批准号:
10679858 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Cell-Intrinsic Mechanisms of Presynaptic Assembly
突触前组装的细胞内在机制
- 批准号:
10786383 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Eph and Lyn hyper-phosphorylation and CRMP interactions in AD"
AD中Eph和Lyn过度磷酸化与CRMP相互作用"
- 批准号:
10746170 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Alternative splicing regulation of CLTC in the heart
心脏中 CLTC 的选择性剪接调节
- 批准号:
10749474 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Affinity purification of cross-ß fibrils using immobilized thioflavin
使用固定化硫代黄素对交叉原纤维进行亲和纯化
- 批准号:
10646061 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:
Regulation of synapse development by small GTPase cascades in Caenorhabditis elegans
秀丽隐杆线虫中小 GTP 酶级联对突触发育的调节
- 批准号:
10735077 - 财政年份:2023
- 资助金额:
$ 17.44万 - 项目类别:














{{item.name}}会员




